Compared with placebo, long-term use of SGLT-2 inhibitors can reduce the risk of CV death or HHF, CV death, HHF, and all-cause mortality in patients with T2DM and HF. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.